8-K
filed January 16, 2024, 6:59 PM ET
ticker ADIL
CIK 0001513525
other material
confidence high
sentiment neutral
materiality 0.15
Adial shareholders approve issuance of up to 3.0M shares upon warrant exercise
ADIAL PHARMACEUTICALS, INC.
- Proposal 1 approved: 432,915 for, 51,550 against, 6,621 abstain; enables exercise of warrants from Oct 2023 private placement.
- Proposal 2 (adjournment) also approved but not needed; votes: 436,338 for, 47,809 against, 6,939 abstain.
- Warrant exercise could dilute existing common stock by over 20%, subject to Nasdaq rules.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ADIAL PHARMACEUTICALS, INC. shareholders approved Approval of adjournment of Special Meeting, if necessary, to permit further solicitation at the 2024-01-11 meeting.
- Outcome
- passed
- Meeting
- 2024-01-11
Exact text from the filing
Proposal 2 : Approval of an adjournment of the Special Meeting to a later date, if necessary, to permit furth solicitation and vote of proxies in the event there are not sufficient votes in favor of the Warrant Exercise Proposal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ADIAL PHARMACEUTICALS, INC. shareholders approved Approval of issuance of up to 3,007,092 shares of common stock upon exercise of warrants in connection with private placement at the 2024-01-11 meeting.
- Outcome
- passed
- Meeting
- 2024-01-11
Exact text from the filing
Proposal 1 : Approval of, pursuant to Nasdaq listing rules, of the issuance of up to an aggregate of 3,007,092 shares of the Company's common stock upon the exercise of common stock purchase warrants issued or issuable to an institutional investor and designees of the placement agent in connection with the Company's private placement offering that closed on October 24, 2023 that may be equal to or exceed 20% of the Company's common stock outstanding before such offering.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.